Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 déc. 2025 09h46 HE | Source: Research and Markets

CAR-T Cell Therapy Forecast Report 2025: A $13.25 Billion Market by 2030, Driven by Rising Cancer Incidence, Strong Efficacy in R/R Patients, and Growing R&D Investment

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
27 nov. 2025 08h57 HE | Source: Research and Markets

Fibroblast Activation Protein (FAP) Targeted Therapy Competitor Analysis Report

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering. This...
27 nov. 2025 08h43 HE | Source: Research and Markets

KLK2-Targeted Immunotherapies Pipeline Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of KLK2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
27 nov. 2025 08h18 HE | Source: Research and Markets

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline and Competitive Intelligence Report 2025: Oncology Applications Using Biomarker-driven Patient Stratification and Combination Treatments

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
21 nov. 2025 07h07 HE | Source: Research and Markets

U.S. Cell and Gene Therapy CDMO Market Trends Analysis Report 2025-2033: Gene & CAR-T Therapy Boom Drives Demand for CDMO Partnerships and Specialized Manufacturing Capacity

Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy,...
05 nov. 2025 15h20 HE | Source: Tevogen Bio Inc

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk...
29 oct. 2025 12h35 HE | Source: Tevogen Bio Inc

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to...
22 oct. 2025 10h44 HE | Source: Research and Markets

T-Cell Malignancies Pipeline Research Report 2025: Market Opportunities with Over 75 Companies and 80+ Drugs, Exploring Novel Treatments Like CAR-T Therapies and Targeted Therapies

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "T-Cell Malignancies - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers in-depth analysis of over 75...
14 oct. 2025 08h00 HE | Source: Tr1X, Inc.

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.
02 oct. 2025 04h17 HE | Source: Research and Markets

Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma

Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and...

Page suivante